BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Feb. 2, 2021

View Archived Issues
Packaging and kit components

Ellume signs $231M supply agreement with U.S. government for COVID-19 home tests

PERTH, Australia –Digital diagnostics company Ellume Ltd. announced a US$231.8 million agreement with the U.S. Department of Defense (DoD), in coordination with the Department of Health and Human Services (HHS), to accelerate domestic U.S. production of its COVID-19 home tests. The agreement includes funding to support the establishment of Ellume’s U.S.-based manufacturing facility and the delivery of 8.5 million COVID-19 home tests that will be distributed across the U.S. Read More
Product image

Visby lands $12.3M for development of POC and consumer versions of combined rapid influenza/COVID-19 PCR test

Visby Medical Inc. secured $12.3 million in funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a next generation device to detect influenza and COVID-19 in a single point-of-care rapid PCR test and, subsequently, as an over-the-counter test for consumer use. The contract may be extended up to a total of $48.7 million over a period of 38 months based on meeting certain milestones in the base period, according to Visby Founder and CEO Adam de la Zerda. Read More
Doctor with brain illustration, businessman with dollar sign illustration

Neurovision Imaging gets funding to advance Alzheimer’s biomarkers

A definitive diagnosis of Alzheimer’s disease often isn’t arrived at until after a patient dies, when their brain is examined during autopsy. Neurovision Imaging Inc. is hoping to change that with reliable, affordable biomarker tests that can detect Alzheimer’s and other forms of dementia and neurodegenerative disorders before symptoms appear. Read More
europe-map.png

$5.2B cash injection for German public hospitals to boost digital health

BERLIN – The German government has just made $3.6 billion available to the Future of Hospitals Act (Krankenhauszukunftsgesetz, KHZG), through the liquidity reserve of the health fund in order to support public hospitals with digital transformation. Besides this government cash injection, an additional $1.6 billion will be made available through co-funding by the German federal states, the 16 Länder. In total, German hospitals will get a $5.2 billion funding to boost digitization. Read More
Woman using smartphone

State medical licensure a potential limiting factor in proliferation of telehealth

The expansions of coverage of telehealth associated with the COVID-19 pandemic will persist after the pandemic is over, even if the post-pandemic utilization does not match the current rates and types of utilization. However, speakers on a recent webinar hosted by Moses & Singer LLP of New York said that state medical licensure practices after the pandemic could be a help or a hindrance to more widespread use of telehealth, an issue stakeholders will want to track as 2021 unwinds. Read More

Appointments and advancements for Feb. 2, 2021

New hires and promotions in the med-tech industry, including: Nuvasive, PhysIQ, Urodev Medical, Vilua, Volitionrx. Read More

Financings for Feb. 2, 2021

Med-tech firms raising money in public or private financings, including: Flosonics Medical, Folx Health, Healthtensor, Plume, Transenterix. Read More

Other news to note for Feb. 2, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accuvein, Adapthealth, Aerocare, Aegea Medical, Biosig, Cardiofocus, Chronix, Coopersurgical, Diagnos, Electrocore, Evestra, Geniemd, Horiba, Intellatriage, Japan Lifeline, Kanhoor Medical, Lidco, Masimo, Mayo Clinic, Medtest, Myriad Genetics, Novacyt, Omega Laboratories, Oncocyte, Predictive Oncology, Vivos Therapeutics. Read More

Regulatory actions for Feb. 2, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Inovytec, Johnson & Johnson Vision. Read More

Regulatory front for Feb. 2, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: CDC reports on cases, sequencing; NICE says savings seen with Cytosorb; IP at issue as WTO pushes for global pandemic effort; Researcher gets prison time for trade secret theft; USPTO responds to COVID-19 challenge. Read More

BioWorld MedTech’s Oncology Extra for Feb. 2, 2021

Keeping you up to date on recent developments in oncology, including: New nanotech approach to skin cancer in development at Yale; Imaging for prediction of response to hormone therapy; Algorithm is predictive of response to immunotherapy. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing